Equecabtagene Autoleucel for relapsed/refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is studying a new treatment called equecabtagene autoleucel for people whose multiple myeloma has come back or stopped responding to other treatments. It aims to see how well this therapy works in real-world medical settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult with multiple myeloma that has relapsed or become resistant to treatment.
- Your doctor has decided that equecabtagene autoleucel is the right treatment for you.
- You can voluntarily sign a consent form agreeing to take part in the study.
- You are not allergic to any ingredient in the treatment, including dimethyl sulfoxide or human albumin.
- Your doctor believes you can keep follow-up appointments and likely live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called Eque-cel, which is designed to target and kill cancer cells in people with multiple myeloma that has returned or is hard to treat after at least three prior therapies. The treatment uses your own immune cells that are modified to fight the myeloma.
This Phase 1 trial tests a new drug called RO7851624 in patients whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to understand how safe and effective this drug is.
This trial tests a new drug called LBL-034 in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new CAR-T cell therapy called LCAR-M61SQ for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It aims to see if this therapy can help control the disease.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.